Trial Profile
Open-label, Randomized, Crossover Clinical Trials for Single Oral Dose of 60mg Fimasartan and Single IV Infusion of 30mg Fimasartan to Evaluate the Absolute Bioavailability of Kanarb Tablet (Fimasartan) in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Jul 2016
Price :
$35
*
At a glance
- Drugs Fimasartan (Primary) ; Fimasartan (Primary)
- Indications Hypertension
- Focus Pharmacokinetics
- 15 Mar 2015 Status changed from recruiting to completed according to an abstract published at the 116th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
- 28 Aug 2012 New trial record